Kezar Life Sciences presents trial data at medical conferences Nov 7, 2025 07:03AM
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 Nov 7, 2025 07:01AM
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences Aug 28, 2025 04:01PM
FDA lifts partial clinical hold on Kezar Life Sciences hepatitis drug trial Jul 15, 2025 04:41PM
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis Jul 15, 2025 04:41PM


May 28, 2025 04:01PM Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 13, 2025 04:01PM Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 25, 2025 07:30AM Kezar Life Sciences (KZR) Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of AIH and Reports Fourth Quarter and Year End 2024 Financial Res
Mar 25, 2025 07:30AM Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter
Mar 24, 2025 08:00AM Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Feb 18, 2025 04:01PM Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus N
Nov 12, 2024 04:01PM Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 28, 2024 08:30AM Kezar Life Sciences (KZR) Announces 1:10 Reverse Share Split
Oct 28, 2024 08:30AM Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Oct 17, 2024 08:35AM Kezar Life Sciences (KZR) Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Oct 17, 2024 08:35AM Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Oct 17, 2024 08:30AM Kezar Life Sciences (KZR) Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib
Oct 17, 2024 08:30AM Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Oct 4, 2024 05:00PM Kezar Life Sciences (KZR) Announces Clinical Hold of Zetomipzomib IND
Oct 4, 2024 05:00PM Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Sep 30, 2024 08:30AM Kezar Life Sciences (KZR) Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib
Sep 30, 2024 08:30AM Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
Sep 4, 2024 04:01PM Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 13, 2024 04:02PM Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 10, 2024 04:01PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Jun 7, 2024 05:59PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 29, 2024 04:01PM Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 9, 2024 04:01PM Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 04:05PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 8, 2024 04:01PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mar 14, 2024 04:01PM Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Mar 8, 2024 04:05PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2024 04:01PM Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Feb 26, 2024 06:30PM Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Feb 26, 2024 06:11PM Kezar Life Sciences (KZR) and Everest Medicines Announce IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Feb 26, 2024 06:10PM Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Nov 21, 2023 04:01PM Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
Nov 13, 2023 04:01PM Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 3, 2023 04:03PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 9, 2023 05:56PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 3, 2023 04:11PM Kezar Life Sciences (KZR) Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as CEO
Oct 3, 2023 04:10PM Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
Sep 20, 2023 07:37PM Kezar Life Sciences (KZR) and Everest Medicines Enter Deal to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asi
Sep 20, 2023 06:30PM Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southe
Aug 31, 2023 04:01PM Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
Aug 10, 2023 04:01PM Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
May 10, 2021 04:01PM  Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work
Nov 5, 2020 08:46AM Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020
Sep 17, 2020 04:01PM Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology
Sep 10, 2020 07:00AM Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology